DNY59 Topline Summary and Update ALX Oncology (NASDAQ:ALXO) is a cancer-focused biotech I've expressed deep skepticism in over the course of various articles, stating unequivocally that I did not feel that the risk to reward ratio was appropriate at the billion-plus market cap that the company was commanding as a phase 2 entity. They had generated compelling findings in their early trial readouts, but the CD47-based approach carries too much baggage for me to get too excited. Since then, the company's valua ...